APL-801

N/A

Report date: 2025/12/19 10:57:02

Base Information

Drug NameAPL-801
Drug Alias NameAPL-801
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockersTumor necrosis factor receptor superfamily member 5 agonists
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesRevMAb Biosciences USA Inc
China Registration ClassN/A

Develop Information

Active CompaniesApollomics IncZhejiang Crownmab Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A